Katja Krauss1, Elmar Stickeler1. 1. Breast Center, Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany.
Abstract
BACKGROUND: Endocrine therapy with a standard duration of 5 years is well known as an effective treatment for endocrine-sensitive breast cancer. SUMMARY: In the adjuvant setting this treatment reduces the 15-year mortality rates by about 30 and 40% with tamoxifen and aromatase inhibitor, respectively. The well-known long-term recurrence risk of luminal cancers led to multiple trials examining the benefit of extended endocrine treatment for up to 15 years. Additional benefit with extended therapy was seen for patients with high recurrence risk. Also, additional ovarian suppression for premenopausal women exhibited a significant benefit for patients at higher risk. KEY MESSAGES: The data of the last years will be summarized and discussed, also considering the side effects of the different treatment options.
BACKGROUND: Endocrine therapy with a standard duration of 5 years is well known as an effective treatment for endocrine-sensitive breast cancer. SUMMARY: In the adjuvant setting this treatment reduces the 15-year mortality rates by about 30 and 40% with tamoxifen and aromatase inhibitor, respectively. The well-known long-term recurrence risk of luminal cancers led to multiple trials examining the benefit of extended endocrine treatment for up to 15 years. Additional benefit with extended therapy was seen for patients with high recurrence risk. Also, additional ovarian suppression for premenopausal women exhibited a significant benefit for patients at higher risk. KEY MESSAGES: The data of the last years will be summarized and discussed, also considering the side effects of the different treatment options.
Authors: K Strasser-Weippl; G Sudan; R Ramjeesingh; L E Shepherd; J O'Shaughnessy; W R Parulekar; P E R Liedke; B E Chen; P E Goss Journal: Eur J Cancer Date: 2017-12-20 Impact factor: 9.162
Authors: Thomas Ruhstaller; Anita Giobbie-Hurder; Marco Colleoni; Maj-Britt Jensen; Bent Ejlertsen; Evandro de Azambuja; Patrick Neven; István Láng; Erik Hugger Jakobsen; Laurence Gladieff; Hervé Bonnefoi; Vernon J Harvey; Simon Spazzapan; Carlo Tondini; Lucia Del Mastro; Corinne Veyret; Edda Simoncini; Lorenzo Gianni; Christoph Rochlitz; Elena Kralidis; Khalil Zaman; Jacek Jassem; Martine Piccart-Gebhart; Angelo Di Leo; Richard D Gelber; Alan S Coates; Aron Goldhirsch; Beat Thürlimann; Meredith M Regan Journal: J Clin Oncol Date: 2018-11-26 Impact factor: 44.544
Authors: Erik J Blok; Judith R Kroep; Elma Meershoek-Klein Kranenbarg; Marjolijn Duijm-de Carpentier; Hein Putter; Joan van den Bosch; Eduard Maartense; A Elise van Leeuwen-Stok; Gerrit-Jan Liefers; Johan W R Nortier; Emiel J Th Rutgers; Cornelis J H van de Velde Journal: J Natl Cancer Inst Date: 2018-01-01 Impact factor: 13.506
Authors: Poornima Saha; Meredith M Regan; Olivia Pagani; Prudence A Francis; Barbara A Walley; Karin Ribi; Jürg Bernhard; Weixiu Luo; Henry L Gómez; Harold J Burstein; Vani Parmar; Roberto Torres; Josephine Stewart; Meritxell Bellet; Antonia Perelló; Faysal Dane; Antonio Moreira; Daniel Vorobiof; Michelle Nottage; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Marco Colleoni; Gini F Fleming Journal: J Clin Oncol Date: 2017-06-27 Impact factor: 44.544
Authors: Matthew J Ellis; Vera J Suman; Jeremy Hoog; Rodrigo Goncalves; Souzan Sanati; Chad J Creighton; Katherine DeSchryver; Erika Crouch; Amy Brink; Mark Watson; Jingqin Luo; Yu Tao; Michael Barnes; Mitchell Dowsett; G Thomas Budd; Eric Winer; Paula Silverman; Laura Esserman; Lisa Carey; Cynthia X Ma; Gary Unzeitig; Timothy Pluard; Pat Whitworth; Gildy Babiera; J Michael Guenther; Zoneddy Dayao; David Ota; Marilyn Leitch; John A Olson; D Craig Allred; Kelly Hunt Journal: J Clin Oncol Date: 2017-01-03 Impact factor: 44.544
Authors: Ivana Sestak; Richard Buus; Jack Cuzick; Peter Dubsky; Ralf Kronenwett; Carsten Denkert; Sean Ferree; Dennis Sgroi; Catherine Schnabel; Frederick L Baehner; Elizabeth Mallon; Mitch Dowsett Journal: JAMA Oncol Date: 2018-04-01 Impact factor: 31.777
Authors: Covadonga Martí; Laura Yébenes; José María Oliver; Elisa Moreno; Laura Frías; Alberto Berjón; Adolfo Loayza; Marcos Meléndez; María José Roca; Vicenta Córdoba; David Hardisson; María Ángeles Rodríguez; José Ignacio Sánchez-Méndez Journal: Curr Oncol Date: 2022-03-23 Impact factor: 3.109